Polypeptide N-acetylgalactosaminyl transferase-3 (GalNAc-T3) has been reportedly expressed in several human adenocarcinomas and is associated with clinicopathological features of tumors. We investigated the clinicopathological significance of GalNAc-T3 in thyroid cancer.
Methods:
We evaluated the expression of GalNAc-T3 in 167 patients with thyroid cancer using a specific antibody and analyzed the association between its expression and clinicopathological features.
Results:
GalNAc-T3 was expressed in 85.8% of normal follicular epithelial cells. In papillary carcinomas, positive staining was observed in 101 (73.7%) cases. Well-differentiated components (papillary and follicular) of papillary carcinomas were significantly more frequently positive than poorly differentiated components (trabecular and solid) (p<0.01), and GalNAc-T3 was highly expressed in papillary carcinomas that had invaded beyond the thyroid capsule (p=0.026). GalNAc-T3 was expressed in 40% and 20% of well and poorly differentiated components of follicular carcinomas, respectively. Thirteen of 15 anaplastic carcinomas were negative for GalNAc-T3 and thyroglobulin. Positive staining for GalNAc-T3 was not observed in any of the medullary carcinomas.
Conclusions:
Our data suggest that GalNAc-T3 expression may be a useful indicator of tumor differentiation in thyroid carcinomas.
ItoK, HanamuraT, MurayamaK, OkadaT, WatanabeT, HaradaM, ItoT, KoyamaH, KanaiT, MaenoK, MochizukiY, AmanoJ. 2012. Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors. Head Neck, 34:230–237.
4.
HakomoriS. 1989. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res, 52:257–331.
5.
NakamoriS, OtaDM, ClearyKR, ShirotaniK, IrimuraT. 1994. MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology, 106:353–361.
6.
HattrupCL, GendlerSJ. 2008. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol, 70:431–457.
7.
DubeDH, BertozziCR. 2005. Glycans in cancer and inflammation—potential for therapeutics and diagnostics. Nat Rev Drug Discov, 4:477–488.
8.
HollingsworthMA, SwansonBJ. 2004. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer, 4:45–60.
9.
OgawaJ, SanoA, KoideS, ShohtsuA. 1994. Relation between recurrence and expression of proliferating cell nuclear antigen, sialyl LewisX, and sialyl Lewis(a) in lung cancer. J Thorac Cardiovasc Surg, 108:329–336.
ItzkowitzSH, BloomEJ, KokalWA, ModinG, HakomoriS, KimYS. 1990. Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer, 66:1960–1966.
12.
NakamoriS, KameyamaM, ImaokaS, FurukawaH, IshikawaO, SasakiY, KabutoT, IwanagaT, MatsushitaY, IrimuraT. 1993. Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res, 53:3632–3637.
13.
NiklinskiJ, FurmanM, LaudanskiJ, KozlowskiM. 1992. Prognostic value of pretreatment CEA, SCC-Ag and CA 19–9 levels in sera of patients with non-small cell lung cancer. Eur J Cancer Prev, 1:401–406.
14.
DiezM, TorresA, MaestroML, OrtegaMD, GomezA, PollanM, LopezJA, PicardoA, HernandoF, BalibreaJL. 1996. Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer. Br J Cancer, 73:1248–1254.
15.
OhgamiA, TsudaT, OsakiT, MitsudomiT, MorimotoY, HigashiT, YasumotoK. 1999. MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence. Ann Thorac Surg, 67:810–814.
16.
BresalierRS, NivY, ByrdJC, DuhQY, ToribaraNW, RockwellRW, DahiyaR, KimYS. 1991. Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis. J Clin Invest, 87:1037–1045.
17.
BresalierRS. 1994. Adhesion molecules and gastrointestinal malignancies. Gastroenterology, 106:1378–1382.
18.
SutherlinME, NishimoriI, CaffreyT, BennettEP, HassanH, MandelU, MackD, IwamuraT, ClausenH, HollingsworthMA. 1997. Expression of three UDP-N-acetyl-alpha-D-galactosamine:polypeptide GalNAc N-acetylgalactosaminyltransferases in adenocarcinoma cell lines. Cancer Res, 57:4744–4748.
19.
HagenFK, Van WuyckhuyseB, TabakLA. 1993. Purification, cloning, and expression of a bovine UDP-GalNAc: polypeptide N-acetyl-galactosaminyltransferase. J Biol Chem, 268:18960–18965.
20.
TarpMA, ClausenH. 2008. Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta, 1780:546–563.
21.
YoshimuraY, NudelmanAS, LeverySB, WandallHH, BennettEP, HindsgaulO, ClausenH, NishimuraS. 2012. Elucidation of the sugar recognition ability of the lectin domain of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 3 by using unnatural glycopeptide substrates. Glycobiology, 22:429–438.
22.
HomaFL, HollanderT, LehmanDJ, ThomsenDR, ElhammerAP. 1993. Isolation and expression of a cDNA clone encoding a bovine UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase. J Biol Chem, 268:12609–12616.
23.
WhiteT, BennettEP, TakioK, SorensenT, BondingN, ClausenH. 1995. Purification and cDNA cloning of a human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase. J Biol Chem, 270:24156–24165.
24.
BennettEP, HassanH, ClausenH. 1996. cDNA cloning and expression of a novel human UDP-N-acetyl-alpha-D-galactosamine. Polypeptide N-acetylgalactosaminyltransferase, GalNAc-t3. J Biol Chem, 271:17006–17012.
25.
OnitsukaK, ShibaoK, NakayamaY, MinagawaN, HirataK, IzumiH, MatsuoK, NagataN, KitazatoK, KohnoK, ItohH. 2003. Prognostic significance of UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-3 (GalNAc-T3) expression in patients with gastric carcinoma. Cancer Sci, 94:32–36.
26.
Dosaka-AkitaH, KinoshitaI, YamazakiK, IzumiH, ItohT, KatohH, NishimuraM, MatsuoK, YamadaY, KohnoK. 2002. N-acetylgalactosaminyl transferase-3 is a potential new marker for non-small cell lung cancers. Br J Cancer, 87:751–755.
27.
ShibaoK, IzumiH, NakayamaY, OhtaR, NagataN, NomotoM, MatsuoK, YamadaY, KitazatoK, ItohH, KohnoK. 2002. Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide galNAc N-acetylgalactosaminyl transferase-3 in relation to differentiation and prognosis in patients with colorectal carcinoma. Cancer, 94:1939–1946.
28.
MiyaharaN, ShodaJ, KawamotoT, FurukawaM, UedaT, TodorokiT, TanakaN, MatsuoK, YamadaY, KohnoK, IrimuraT. 2004. Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase isozyme 3 in the subserosal layer correlates with postsurgical survival of pathological tumor stage 2 carcinoma of the gallbladder. Clin Cancer Res, 10:2090–2099.
29.
InoueT, EguchiT, OdaY, NishiyamaK, FujiiK, IzumiH, KohnoK, YamaguchiK, TanakaM, TsuneyoshiM. 2007. Expression of GalNAc-T3 and its relationships with clinicopathological factors in 61 extrahepatic bile duct carcinomas analyzed using stepwise sections—special reference to its association with lymph node metastases. Mod Pathol, 20:267–276.
30.
YamamotoS, NakamoriS, TsujieM, TakahashiY, NaganoH, DonoK, UmeshitaK, SakonM, TomitaY, HoshidaY, AozasaK, KohnoK, MondenM. 2004. Expression of uridine diphosphate N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase 3 in adenocarcinoma of the pancreas. Pathobiology, 71:12–18.
31.
IshikawaM, KitayamaJ, KohnoK, NagawaH. 2005. The expression pattern of UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetyl-galactosaminyl transferase-3 in squamous cell carcinoma of the esophagus. Pathobiology, 72:139–145.
32.
NomotoM, IzumiH, IseT, KatoK, TakanoH, NagataniG, ShibaoK, OhtaR, ImamuraT, KuwanoM, MatsuoK, YamadaY, ItohH, KohnoK. 1999. Structural basis for the regulation of UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase-3 gene expression in adenocarcinoma cells. Cancer Res, 59:6214–6222.
AreC, ShahaAR. 2006. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol, 13:453–464.
35.
van de GraafSA, PauwsE, de VijlderJJ, Ris-StalpersCR. 1997. The revised 8307 base pair coding sequence of human thyroglobulin transiently expressed in eukaryotic cells. Eur J Endocrinol, 136:508–515.
36.
YangSX, PollockHG, RawitchAB. 1996. Glycosylation in human thyroglobulin: location of the N-linked oligosaccharide units and comparison with bovine thyroglobulin. Arch Biochem Biophys, 327:61–70.
37.
WhitleyRJ, AinKB. 2004. Thyroglobulin: a specific serum marker for the management of thyroid carcinoma. Clin Lab Med, 24:29–47.
38.
LinJD. 2008. Thyroglobulin and human thyroid cancer. Clin Chim Acta, 388:15–21.
39.
TarutaniO, UiN. 1985. Properties of thyroglobulins from normal thyroid and thyroid tumor on a concanavalin A-sepharose column. J Biochem, 98:851–857.
40.
ShimizuK, NakamuraK, KobatakeS, SatomuraS, MaruyamaM, KamekoF, TajiriJ, KatoR. 2007. The clinical utility of Lens culinaris agglutinin-reactive thyroglobulin ratio in serum for distinguishing benign from malignant conditions of the thyroid. Clin Chim Acta, 379:101–104.
41.
KanaiT, AmakawaM, KatoR, ShimizuK, NakamuraK, ItoK, HamaY, FujimoriM, AmanoJ. 2009. Evaluation of a new method for the diagnosis of alterations of Lens culinaris agglutinin binding of thyroglobulin molecules in thyroid carcinoma. Clin Chem Lab Med, 47:1285–1290.
42.
RosaiJ. 2003. Immunohistochemical markers of thyroid tumors: significance and diagnostic applications. Tumori, 89:517–519.
43.
OrdonezNG, El-NaggarAK, HickeyRC, SamaanNA. 1991. Anaplastic thyroid carcinoma. Immunocytochemical study of 32 cases. Am J Clin Pathol, 96:15–24.
44.
WisemanSM, MasoudiH, NiblockP, TurbinD, RajputA, HayJ, BugisS, FilipenkoD, HuntsmanD, GilksB. 2007. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol, 14:719–729.
